HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a $200 price target.
August 01, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Jazz Pharmaceuticals and maintained a $200 price target.
The reiteration of a Buy rating and the maintenance of a $200 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price of Jazz Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100